These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16644583)

  • 1. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia.
    Stapnes C; Ryningen A; Gjertsen BT; Bruserud Ø
    Acta Oncol; 2006; 45(3):346-9. PubMed ID: 16644583
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report.
    Anensen N; Skavland J; Stapnes C; Ryningen A; Børresen-Dale AL; Gjertsen BT; Bruserud Ø
    Leukemia; 2006 Apr; 20(4):734-6. PubMed ID: 16437140
    [No Abstract]   [Full Text] [Related]  

  • 3. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
    Ryningen A; Stapnes C; Lassalle P; Corbascio M; Gjertsen BT; Bruserud O
    Leuk Res; 2009 Jun; 33(6):779-87. PubMed ID: 19007987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
    Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
    Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
    Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
    Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
    Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
    Raffoux E; Chaibi P; Dombret H; Degos L
    Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
    Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
    Soriano AO; Yang H; Faderl S; Estrov Z; Giles F; Ravandi F; Cortes J; Wierda WG; Ouzounian S; Quezada A; Pierce S; Estey EH; Issa JP; Kantarjian HM; Garcia-Manero G
    Blood; 2007 Oct; 110(7):2302-8. PubMed ID: 17596541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
    Qi H; Ratnam M
    Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia.
    Shin HJ; Chung JS; Choi YJ; Cho GJ
    Am J Clin Oncol; 2009 Jun; 32(3):227-32. PubMed ID: 19433969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
    Bellos F; Mahlknecht U
    Onkologie; 2008 Nov; 31(11):629-33. PubMed ID: 19145098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of acute promyelocytic leukemia with all-trans retinoic acid].
    Huang ME
    Zhonghua Yi Xue Za Zhi; 1988 Mar; 68(3):131-3, 10. PubMed ID: 3136889
    [No Abstract]   [Full Text] [Related]  

  • 14. [Development of Sweet syndrome in an acute promyelocyte leukemia patient during treatment with all-trans retinoic acid--case report and literature review].
    Yan ZS; Li DP; Jiang EL; Zhou CL; Liu EB; Chen HS; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):462-5. PubMed ID: 18072629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid for the treatment of myeloid malignancies.
    Kuendgen A; Gattermann N
    Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypercalcemia associated with all-trans retinoic acid therapy for microgranular type acute promyelocytic leukemia].
    Hisatake J; Shimozuma J
    Rinsho Ketsueki; 2008 Jun; 49(6):408-12. PubMed ID: 18646608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
    Reikvam H; Hovland R; Forthun RB; Erdal S; Gjertsen BT; Fredly H; Bruserud Ø
    BMC Cancer; 2017 Sep; 17(1):630. PubMed ID: 28877686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.
    Grønningsæter IS; Fredly HK; Gjertsen BT; Hatfield KJ; Bruserud Ø
    Cells; 2019 Oct; 8(10):. PubMed ID: 31658693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of retinoic acid syndrome with dexamethasone: a case report.
    Leelasiri A; Numbenjapol T; Prayoonwiwat W; Mongkolsritrakul W; Srisawat C
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S302-10. PubMed ID: 16858973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.